Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Background: Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint
inhibitors (ICI). Myocarditis after ICI has not been well characterized. Objectives: The authors …

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …

Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the …

Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-
associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …